International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-1 doi: 10.5281/zenodo.13371597
Original Research Article
EFFECT OF DEVIATED NASAL SEPTUM ON TYMPANOPLASTY GRAFT UPTAKE
Published
Feb. 27, 2025
Abstract

BACKGROUND: Chronic suppurative otitis media (CSOM) is commonly treated with tympanoplasty, which has a reported success rate of 85-90%. Success is influenced by various factors, including graft material and surgical technique. The Eustachian tube, vital for middle ear function, can be affected by nasal issues such as deviated nasal septum (DNS), which may impact middle ear ventilation. DNS prevalence is around 22.83%, leading to questions about its effect on tympanoplasty outcomes. MATERIALS AND METHODS: A prospective study was conducted on 50 CSOM patients, divided into two groups based on DNS presence (25 with DNS, 25 without). Patients underwent tympanoplasty using the underlay technique with temporalis fascia graft and were followed for six months to assess graft uptake through otoscopy, microscopy, and audiometry. RESULTS: No significant differences in hearing gain (p=0.3) or graft uptake (p=0.13) were found between the two groups. The A-B gap(air-bone gap) also showed no significant difference (p=0.08). CONCLUSION: The study suggests that DNS may not significantly affect tympanoplasty outcomes, challenging the need for pre-tympanoplasty septoplasty. Larger studies are recommended for further exploration.

Recommended Articles
Loading Image...
Volume-6, Issue-1
Citations
1481 Views
208 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved